Carmen Behrens
Papers
1
Total Citations
49
H-Index
1
About
Carmen Behrens is a leading translational researcher whose work focuses on the molecular mechanisms of lung cancer, with a particular emphasis on cell cycle dysregulation and targeted therapies. Her major contributions center on the development and mechanistic understanding of next-generation cyclin-dependent kinase (CDK) inhibitors. In her highly cited 2016 study, Behrens demonstrated that the novel CDK2/9 inhibitor CCT68127 induces anaphase catastrophe—a form of mitotic cell death triggered by supernumerary centrosomes—in lung cancer cells, offering a promising therapeutic strategy over first-generation agents like seliciclib. This work, which has garnered 49 citations, has been instrumental in advancing the field of CDK-targeted cancer therapy. Behrens’ research bridges preclinical drug development and clinical application, providing critical insights into how lung tumors with centrosome amplification can be selectively targeted. Her findings have implications for overcoming drug resistance and improving treatment outcomes in non-small cell lung cancer, establishing her as a key figure in thoracic oncology and cell cycle biology.
Research Focus
Key Achievements
Top Papers
- 1Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer49 citations · 2016